Cyclerion Therapeutics
CYCN
103 hedge funds and large institutions have $223M invested in Cyclerion Therapeutics in 2019 Q2 according to their latest regulatory filings, with 103 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.55% more ownership
Funds ownership: 0% → 3.55% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.8M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$22.1M |
| 4 |
MP
MFN Partners
Boston,
Massachusetts
|
+$21.1M |
| 5 |
BlackRock
New York
|
+$20.9M |
Top Sellers
CYCN Hedge Fund Activity: Q2 2019 in Review
103 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q2 2019, worth a combined $223M.
Buyers outnumbered sellers: 103 funds opened new CYCN positions and 0 closed out — a net gain of 103 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $38.7M.
- 103 institutional investors held Cyclerion Therapeutics (CYCN) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $223M of Cyclerion Therapeutics stock for Q2 2019.
- 103 funds opened new Cyclerion Therapeutics positions in Q2 2019 and 0 closed out, a net change of +103 holders.
- The largest Cyclerion Therapeutics buyer in Q2 2019 was Fidelity Investments, an estimated $38.7M added.
Based on aggregated 13F filings for Q2 2019.